Eiger BioPharmaceuticals Stock Price, News & Analysis (NASDAQ:EIGR)

$11.05 0.35 (3.27 %)
(As of 11/22/2017 07:26 AM ET)
Previous Close$10.70
Today's Range$10.60 - $11.20
52-Week Range$6.10 - $13.95
Volume34,700 shs
Average Volume54,078 shs
Market Capitalization$112.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.54

About Eiger BioPharmaceuticals (NASDAQ:EIGR)

Eiger BioPharmaceuticals logoEiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:EIGR
  • CUSIP: N/A
  • Web: www.eigerbio.com
Debt:
  • Debt-to-Equity Ratio: 1.19%
  • Current Ratio: 5.78%
  • Quick Ratio: 5.78%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $1.19 per share
  • Price / Book: 9.29
Profitability:
  • Trailing EPS: ($5.30)
  • Net Income: $-47,080,000.00
  • Return on Equity: -169.16%
  • Return on Assets: -95.71%
Misc:
  • Employees: 20
  • Outstanding Shares: 10,520,000
 

Frequently Asked Questions for Eiger BioPharmaceuticals (NASDAQ:EIGR)

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.28) by $0.18. View Eiger BioPharmaceuticals' Earnings History.

Where is Eiger BioPharmaceuticals' stock going? Where will Eiger BioPharmaceuticals' stock price be in 2017?

6 analysts have issued 1 year target prices for Eiger BioPharmaceuticals' stock. Their forecasts range from $27.00 to $36.00. On average, they anticipate Eiger BioPharmaceuticals' share price to reach $33.00 in the next twelve months. View Analyst Ratings for Eiger BioPharmaceuticals.

What are Wall Street analysts saying about Eiger BioPharmaceuticals stock?

Here are some recent quotes from research analysts about Eiger BioPharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (10/17/2017)
  • 2. Wedbush analysts commented, "The Wedbush View: With four drug candidates being tested in four indications and enough cash runway to cover data readouts over the next 12 months, we believe EIGR is trading at an attractive value and recommend shares to investors." (6/21/2017)

Who are some of Eiger BioPharmaceuticals' key competitors?

Who are Eiger BioPharmaceuticals' key executives?

Eiger BioPharmaceuticals' management team includes the folowing people:

  • David A Cory, President, Chief Executive Officer, Director (Age 52)
  • James H. Welch, Chief Financial Officer (Age 58)
  • Rebecque J. Laba, Vice President - Corporate Operations (Age 53)
  • Jeffrey J. Rudy, Vice President - Clinical Operations (Age 53)
  • Ryan K. Takeya, Vice President - Manufacturing (Age 46)
  • James P. Shaffer, Chief Business Officer (Age 49)
  • David Apelian M.D., Ph.D.,, Director (Age 51)
  • Charles Bramlage, Director
  • Thomas J. Dietz, Director
  • Jeffrey S. Glenn, Director

Who owns Eiger BioPharmaceuticals stock?

Eiger BioPharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include PROSIGHT MANAGEMENT, LP (6.90%), Sphera Funds Management LTD. (6.22%), P.A.W. Capital Corp (0.96%), OxFORD Asset Management LLP (0.13%), JPMorgan Chase & Co. (0.14%) and Wedbush Securities Inc. (0.12%). Company insiders that own Eiger BioPharmaceuticals stock include James H Welch, James P Shaffer, Jeffrey S Glenn and Ventures Fund Vi LP Vivo. View Institutional Ownership Trends for Eiger BioPharmaceuticals.

Who bought Eiger BioPharmaceuticals stock? Who is buying Eiger BioPharmaceuticals stock?

Eiger BioPharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., P.A.W. Capital Corp, OxFORD Asset Management LLP, Wedbush Securities Inc. and JPMorgan Chase & Co.. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include James H Welch, James P Shaffer, Jeffrey S Glenn and Ventures Fund Vi LP Vivo. View Insider Buying and Selling for Eiger BioPharmaceuticals.

How do I buy Eiger BioPharmaceuticals stock?

Shares of Eiger BioPharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eiger BioPharmaceuticals' stock price today?

One share of Eiger BioPharmaceuticals stock can currently be purchased for approximately $11.05.

How big of a company is Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals has a market capitalization of $112.53 million. The biotechnology company earns $-47,080,000.00 in net income (profit) each year or ($5.30) on an earnings per share basis. Eiger BioPharmaceuticals employs 20 workers across the globe.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 350 CAMBRIDGE AVENUE SUITE 350, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]


MarketBeat Community Rating for Eiger BioPharmaceuticals (NASDAQ EIGR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  117 (Vote Underperform)
Total Votes:  286
MarketBeat's community ratings are surveys of what our community members think about Eiger BioPharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Eiger BioPharmaceuticals (NASDAQ:EIGR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $33.00 (198.64% upside)

Consensus Price Target History for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Price Target History for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Analysts' Ratings History for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/25/2017WedbushReiterated RatingBuyN/AView Rating Details
10/23/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$34.00N/AView Rating Details
10/19/2017Roth CapitalInitiated CoverageBuy -> Buy$35.00N/AView Rating Details
8/15/2017Piper Jaffray CompaniesReiterated RatingBuy$36.00LowView Rating Details
7/14/2017BTIG ResearchInitiated CoverageBuy$32.00HighView Rating Details
5/15/2017Jefferies Group LLCReiterated RatingBuy$28.00 -> $27.00MediumView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Earnings by Quarter for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Earnings History by Quarter for Eiger BioPharmaceuticals (NASDAQ EIGR)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($1.28)($1.10)ViewN/AView Earnings Details
8/14/2017Q2 2017($1.28)($1.33)ViewN/AView Earnings Details
5/12/2017Q1 2017($1.35)($1.34)ViewN/AView Earnings Details
3/23/2017Q4 2016($1.38)($1.53)ViewN/AView Earnings Details
11/8/2016Q3 2016($1.21)($1.49)ViewN/AView Earnings Details
8/10/2016Q2($1.17)($1.87)ViewN/AView Earnings Details
5/16/2016Q1($1.69)($10.42)ViewN/AView Earnings Details
8/11/2015Q2($0.32)($0.69)ViewN/AView Earnings Details
3/31/2015Q414($0.36)($0.49)ViewN/AView Earnings Details
11/12/2014Q3 2014($0.39)($0.40)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.39)($0.38)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.44)($0.58)ViewN/AView Earnings Details
3/31/2014Q4 2013($0.47)($7.96)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eiger BioPharmaceuticals (NASDAQ:EIGR)
2017 EPS Consensus Estimate: ($4.93)
2018 EPS Consensus Estimate: ($4.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.37)($1.10)($1.24)
Q2 20173($1.51)($0.93)($1.21)
Q3 20173($1.33)($1.04)($1.22)
Q4 20173($1.48)($1.07)($1.27)
Q1 20181($1.14)($1.14)($1.14)
Q2 20181($1.14)($1.14)($1.14)
Q3 20181($1.14)($1.14)($1.14)
Q4 20181($1.14)($1.14)($1.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Eiger BioPharmaceuticals (NASDAQ:EIGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Eiger BioPharmaceuticals (NASDAQ EIGR)

Insider Ownership Percentage: 28.80%
Institutional Ownership Percentage: 49.59%
Insider Trades by Quarter for Eiger BioPharmaceuticals (NASDAQ:EIGR)
Institutional Ownership by Quarter for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Insider Trades by Quarter for Eiger BioPharmaceuticals (NASDAQ EIGR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2017Jeffrey S GlennDirectorBuy15,000$9.53$142,950.00View SEC Filing  
11/18/2016Jeffrey S GlennDirectorBuy15,460$12.74$196,960.40View SEC Filing  
8/18/2016James P ShafferInsiderBuy3,125$15.70$49,062.50View SEC Filing  
8/18/2016Ventures Fund Vi L.P. VivoMajor ShareholderBuy187,500$16.00$3,000,000.00View SEC Filing  
6/22/2016James H WelchCFOBuy2,500$19.80$49,500.00View SEC Filing  
6/13/2016James P ShafferInsiderBuy1,250$22.17$27,712.50View SEC Filing  
5/23/2016James P ShafferInsiderBuy1,245$19.80$24,651.00View SEC Filing  
4/6/2015Krisztina M ZseboCEOSell47,931$18.20$872,344.20View SEC Filing  
4/2/2015Rebecque J LabaVPSell11,012$17.30$190,507.60View SEC Filing  
3/9/2015Krisztina M ZseboCEOSell47,931$24.80$1,188,688.80View SEC Filing  
3/6/2015Peter HonigDirectorSell9,700$23.74$230,278.00View SEC Filing  
3/6/2015Rebecque J LabaVPSell14,000$23.06$322,840.00View SEC Filing  
3/2/2015Ryan K TakeyaVPSell7,777$18.48$143,718.96View SEC Filing  
2/9/2015Krisztina M ZseboCEOSell47,931$15.86$760,185.66View SEC Filing  
2/6/2015Rebecque J LabaVPSell14,000$16.08$225,120.00View SEC Filing  
2/2/2015Ryan K TakeyaVPSell7,777$16.35$127,153.95View SEC Filing  
1/9/2015Jeffrey J RudyVPSell10,000$18.51$185,100.00View SEC Filing  
1/7/2015Rebecque J LabaVPSell20,000$17.30$346,000.00View SEC Filing  
1/6/2015Krisztina M ZseboCEOSell41,302$17.51$723,198.02View SEC Filing  
1/2/2015Ryan K TakeyaVPSell7,777$19.88$154,606.76View SEC Filing  
12/9/2014Jeffrey J RudyVPSell10,000$15.00$150,000.00View SEC Filing  
12/9/2014Krisztina M ZseboCEOSell41,302$15.00$619,530.00View SEC Filing  
12/5/2014Rebecque J LabaVPSell20,000$12.77$255,400.00View SEC Filing  
12/1/2014Ryan K TakeyaVPSell7,777$12.01$93,401.77View SEC Filing  
2/4/2014Enterprise Partners ManagementMajor ShareholderBuy133,083$8.00$1,064,664.00View SEC Filing  
2/4/2014Fredrik WiklundVPBuy20,000$8.00$160,000.00View SEC Filing  
2/4/2014Todd FoleyDirectorBuy111,608$8.00$892,864.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eiger BioPharmaceuticals (NASDAQ EIGR)

Source:
DateHeadline
Eiger BioPharmaceuticals (EIGR) Presents At Jefferies 2017 London Healthcare Conference - SlideshowEiger BioPharmaceuticals (EIGR) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 4:58 PM
Eiger BioPharmaceuticals, Inc. (EIGR) Receives Average Recommendation of "Buy" from BrokeragesEiger BioPharmaceuticals, Inc. (EIGR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 16 at 8:00 AM
Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare ConferenceEiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference
finance.yahoo.com - November 13 at 11:39 AM
Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results - PR Newswire (press release)Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - November 11 at 9:13 AM
Eiger BioPharmaceuticals, Inc. (EIGR) Releases Quarterly  Earnings Results, Beats Estimates By $0.18 EPSEiger BioPharmaceuticals, Inc. (EIGR) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS
www.americanbankingnews.com - November 10 at 7:32 PM
Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial ResultsEiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 10 at 12:03 PM
Should Your Next Investment In The Healthcare Industry Be In Eiger BioPharmaceuticals Inc (EIGR)?Should Your Next Investment In The Healthcare Industry Be In Eiger BioPharmaceuticals Inc (EIGR)?
finance.yahoo.com - November 8 at 5:49 AM
Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences - PR Newswire (press release)Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences - PR Newswire (press release)
www.prnewswire.com - November 6 at 7:44 PM
Does Eiger BioPharmaceuticals Inc’s (EIGR) Debt Level Pose A Serious Problem?Does Eiger BioPharmaceuticals Inc’s (EIGR) Debt Level Pose A Serious Problem?
finance.yahoo.com - November 6 at 7:44 PM
Eiger BioPharmaceuticals to Participate in Upcoming Investor ConferencesEiger BioPharmaceuticals to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 6 at 7:44 PM
Eiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriters Option to Purchase Additional SharesEiger BioPharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise In Full of Underwriter's Option to Purchase Additional Shares
finance.yahoo.com - October 31 at 7:25 PM
Eiger BioPharmaceuticals, Inc. (EIGR) Set to Announce Quarterly Earnings on MondayEiger BioPharmaceuticals, Inc. (EIGR) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:15 AM
Eiger BioPharmaceuticals (EIGR) Prices 1.85M Offering of Common Stock at $10/ShareEiger BioPharmaceuticals (EIGR) Prices 1.85M Offering of Common Stock at $10/Share
www.streetinsider.com - October 28 at 11:31 PM
Eiger BioPharmaceuticals (EIGR) Prices 1.85M Offering of Common Stock at $10/Share - StreetInsider.comEiger BioPharmaceuticals (EIGR) Prices 1.85M Offering of Common Stock at $10/Share - StreetInsider.com
www.streetinsider.com - October 27 at 3:21 PM
Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common StockEiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 27 at 3:21 PM
Eiger BioPharmaceuticals (EIGR) Plans Public Offering of Common Stock - StreetInsider.comEiger BioPharmaceuticals (EIGR) Plans Public Offering of Common Stock - StreetInsider.com
www.streetinsider.com - October 27 at 4:34 AM
Eiger BioPharmaceuticals Announces Proposed Public Offering of Common StockEiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 26 at 6:27 PM
Eiger BioPharmaceuticals, Inc. (EIGR) Receives Buy Rating from WedbushEiger BioPharmaceuticals, Inc. (EIGR) Receives Buy Rating from Wedbush
www.americanbankingnews.com - October 25 at 10:28 PM
Contrasting Metabolix (YTEN) & Eiger BioPharmaceuticals (EIGR)Contrasting Metabolix (YTEN) & Eiger BioPharmaceuticals (EIGR)
www.americanbankingnews.com - October 25 at 10:44 AM
32 Stocks Moving In Mondays Mid-Day Session - Benzinga32 Stocks Moving In Monday's Mid-Day Session - Benzinga
www.benzinga.com - October 23 at 3:53 PM
Eiger BioPharmaceuticals (EIGR) Reports Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in ... - StreetInsider.comEiger BioPharmaceuticals (EIGR) Reports Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in ... - StreetInsider.com
www.streetinsider.com - October 23 at 3:53 PM
Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) MeetingEiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting
finance.yahoo.com - October 23 at 3:53 PM
Oppenheimer Holdings, Inc. Analysts Give Eiger BioPharmaceuticals, Inc. (EIGR) a $34.00 Price TargetOppenheimer Holdings, Inc. Analysts Give Eiger BioPharmaceuticals, Inc. (EIGR) a $34.00 Price Target
www.americanbankingnews.com - October 23 at 1:08 PM
Eiger BioPharmaceuticals, Inc. (EIGR) Expected to Post Earnings of -$1.27 Per ShareEiger BioPharmaceuticals, Inc. (EIGR) Expected to Post Earnings of -$1.27 Per Share
www.americanbankingnews.com - October 23 at 10:30 AM
Eiger BioPharmaceuticals, Inc. (EIGR) Receives Consensus Rating of "Buy" from BrokeragesEiger BioPharmaceuticals, Inc. (EIGR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 22 at 8:36 AM
Eiger BioPharmaceuticals, Inc. (EIGR) Now Covered by Analysts at Roth CapitalEiger BioPharmaceuticals, Inc. (EIGR) Now Covered by Analysts at Roth Capital
www.americanbankingnews.com - October 19 at 11:45 AM
Eiger BioPharmaceuticals, Inc. (EIGR) Stock Rating Lowered by Zacks Investment ResearchEiger BioPharmaceuticals, Inc. (EIGR) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 17 at 6:30 PM
Eiger BioPharmaceuticals, Inc. (EIGR) Raised to Buy at Zacks Investment ResearchEiger BioPharmaceuticals, Inc. (EIGR) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - October 16 at 6:46 PM
Eiger BioPharmaceuticals (EIGR) Announces Abstracts and Presentations at AASLDEiger BioPharmaceuticals (EIGR) Announces Abstracts and Presentations at AASLD
www.streetinsider.com - October 4 at 10:17 AM
Eiger BioPharmaceuticals (EIGR) Announces Abstracts and Presentations at AASLD - StreetInsider.comEiger BioPharmaceuticals (EIGR) Announces Abstracts and Presentations at AASLD - StreetInsider.com
www.streetinsider.com - October 3 at 10:57 AM
Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) MeetingEiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting
finance.yahoo.com - October 3 at 10:57 AM
Eiger BioPharmaceuticals, Inc. (EIGR) Given Average Recommendation of "Hold" by BrokeragesEiger BioPharmaceuticals, Inc. (EIGR) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 27 at 8:43 AM
Oppenheimer Holdings, Inc. Reiterates "Buy" Rating for Eiger BioPharmaceuticals, Inc. (EIGR)Oppenheimer Holdings, Inc. Reiterates "Buy" Rating for Eiger BioPharmaceuticals, Inc. (EIGR)
www.americanbankingnews.com - September 25 at 4:44 PM
Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors - PR Newswire (press release)Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors - PR Newswire (press release)
www.prnewswire.com - September 19 at 11:14 PM
Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of DirectorsEiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors
finance.yahoo.com - September 18 at 6:03 PM
Contrasting Eiger BioPharmaceuticals (EIGR) & Its RivalsContrasting Eiger BioPharmaceuticals (EIGR) & Its Rivals
www.americanbankingnews.com - September 15 at 2:14 AM
Eiger BioPharmaceuticals (EIGR) Presents At 24th Annual NewsMakers in the Biotech Industry - SlideshowEiger BioPharmaceuticals (EIGR) Presents At 24th Annual NewsMakers in the Biotech Industry - Slideshow
seekingalpha.com - September 11 at 6:48 PM
Eiger BioPharmaceuticals, Inc. (EIGR) Director Jeffrey S. Glenn Buys 15,000 SharesEiger BioPharmaceuticals, Inc. (EIGR) Director Jeffrey S. Glenn Buys 15,000 Shares
www.americanbankingnews.com - September 5 at 8:08 PM
Eiger BioPharmaceuticals (EIGR) Granted FDA Orphan Drug Designation for LambdaEiger BioPharmaceuticals (EIGR) Granted FDA Orphan Drug Designation for Lambda
www.streetinsider.com - September 5 at 7:48 PM
Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus InfectionEiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
finance.yahoo.com - September 5 at 7:48 PM
Eiger BioPharmaceuticals to Present at Two Upcoming Investor ConferencesEiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences
finance.yahoo.com - August 30 at 7:26 PM
-$1.26 Earnings Per Share Expected for Eiger BioPharmaceuticals, Inc. (EIGR) This Quarter-$1.26 Earnings Per Share Expected for Eiger BioPharmaceuticals, Inc. (EIGR) This Quarter
www.americanbankingnews.com - August 28 at 10:28 AM
BRIEF-Sphera Funds Management reports 5.35 pct passive stake in Eiger BiopharmaceuticalsBRIEF-Sphera Funds Management reports 5.35 pct passive stake in Eiger Biopharmaceuticals
www.reuters.com - August 24 at 7:10 PM
Q3 2017 EPS Estimates for Eiger BioPharmaceuticals, Inc. Reduced by Oppenheimer Holdings (EIGR)Q3 2017 EPS Estimates for Eiger BioPharmaceuticals, Inc. Reduced by Oppenheimer Holdings (EIGR)
www.americanbankingnews.com - August 18 at 6:42 AM
Eiger BioPharmaceuticals (EIGR) Presents At Wedbush PacGrow Healthcare Conference - SlideshowEiger BioPharmaceuticals (EIGR) Presents At Wedbush PacGrow Healthcare Conference - Slideshow
seekingalpha.com - August 18 at 12:31 AM
Eiger BioPharmaceuticals, Inc. Forecasted to Post Q3 2017 Earnings of ($1.29) Per Share (EIGR)Eiger BioPharmaceuticals, Inc. Forecasted to Post Q3 2017 Earnings of ($1.29) Per Share (EIGR)
www.americanbankingnews.com - August 16 at 6:46 AM
Research Analysts Issue Forecasts for Eiger BioPharmaceuticals, Inc.s Q3 2017 Earnings (EIGR)Research Analysts Issue Forecasts for Eiger BioPharmaceuticals, Inc.'s Q3 2017 Earnings (EIGR)
www.americanbankingnews.com - August 16 at 6:46 AM
Eiger BioPharmaceuticals, Inc. (EIGR) Announces  Earnings Results, Misses Expectations By $0.05 EPSEiger BioPharmaceuticals, Inc. (EIGR) Announces Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - August 15 at 12:46 PM
Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial ResultsEiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 6:35 PM
Eiger BioPharma reports 2Q lossEiger BioPharma reports 2Q loss
finance.yahoo.com - August 14 at 6:35 PM

Social Media

Financials

Chart

Eiger BioPharmaceuticals (NASDAQ EIGR) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.